DRKS00030731招募中不适用
COvid-19: Influence of JAK-inhibitors on the vaccination efficiency against SARS-CoV-2 - Comparison of pan-JAK- and selective JAK1-inhibitors - SAVIOUR
KSH Kiel0 个研究点目标入组 120 人开始时间: 2022年11月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •patients diagnosed with rheumatoid arthritis fulfilling ACR criteria who use either Filgotinib, Baracitinib, Upadicitinib, Tofacitinib or a TNF blocker. Inactive or low disease activity (DAS28-CRP<4)
- •A vaccination against SARS-COV-2 with omicron-adapted mRNA vaccines is planned.
排除标准
- •malignant diseases, other autoimmune diseases like CED, MS, diabetes type 1, prednisolone dose above 7.5mg/d
研究者
相似试验
尚未招募
不适用
Influence of JAK inhibitors on the disease-associated network of intestinal immune cells in ulcerative colitisUlcerative ColitisNL-OMON51787eids Universitair Medisch Centrum70
招募中
4 期
Investigating the role of JAK inhibition in achieving and maintaining disease remission in psoriatic arthritis (PsA).Psoriatic Arthritis2024-511401-40-00UZ Leuven20
进行中（未招募）
1 期
Investigating the role of JAK inhibition in achieving and maintaining disease remission in psoriatic arthritis (PsA).MedDRA version: 21.0Level: LLTClassification code: 10037160Term: Psoriatic arthritis Class: 10028395Psoriatic ArthritisCTIS2024-511401-40-00Z Leuven20
进行中（未招募）
不适用
A Randomized Study of the JAK Inhibitor INCB018424 Tablets Compared to Best Available Therapy in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) - COMFORT IIMedDRA version: 12.0Level: LLTClassification code 10028537Term: MyelofibrosisMyelofibrosisEUCTR2009-009858-24-ITIncyte Corporation150
进行中（未招募）
1 期
The effect of the new anti-rheumatic drug tofacitinib on cytokine-induced inflammatory pathways in patients with rheumatoid arthritisRheumatoid arthritisEUCTR2017-002753-11-FITampere University Hospital24